

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Medical Director <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Stephen J. Thomas, M.D., Edson D. Moreira Jr., M.D., Nicholas Kitchin, M.D., Judith Absalon, M.D., Alejandra Gurtman, M.D., Stephen Lockhart, D.M., John L. Perez, M.D., Gonzalo Pérez Marc, M.D., Fernando P. Polack, M.D., Cristiano Zerbini, M.D., Ruth Bailey, B.Sc., Kena A. Swanson, Ph.D., Xia Xu, Ph.D., Satrajit Roychoudhury, Ph.D., Kenneth Koury, Ph.D., Salim Bouguermouh, M.D., Ph.D., Warren V. Kalina, Ph.D., David Cooper, Ph.D., Robert W. Frencck, Jr., M.D., Laura L. Hammitt, M.D., Özlem Türeci, M.D., Haylene Nell, M.D., Axel Schaefer, M.D., Serhat Únal, M.D., Qi Yang, Ph.D., Paul Liberator, Ph.D., Dina B. Tresnan, D.V.M., Ph.D., Susan Mather, M.D., Philip R. Dormitzer, M.D., Ph.D., Uğur Şahin, M.D.; William C. Gruber, M.D., Kathrin U. Jansen, Ph.D.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director <i>Additional Information:</i>		<i>Position Description:</i> Clinical Scientist
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Associate Director Clinical Research		<i>Position Description:</i> Provide medical and scientific expertise and oversight for global clinical vaccine trials
<i>Additional Information:</i>		
Pfizer	Other	Self
<i>Category:</i> Other		<i>Description:</i> Medical monitor
<i>Additional Information:</i>		
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Vaccine Researcher
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President and Chief Scientific Officer Viral and RNA Vaccines <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Grant / Contract	Self

Recipient Name: Cincinnati Children's Hospital Medical Center
Grant / Contract Description: Clinical Trial grant for COVID-19 vaccines
Additional Information:

Recipient Type: Institution
Grant / Contract Purpose: Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Vice President		<i>Position Description:</i> Vaccine Clinical Research and Development Worldwide Research Development and Medical
<i>Additional Information:</i>		
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> VP Vaccine Clinical Research and Development		<i>Position Description:</i>
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
MedImmune	Grant / Contract	Other - Institution
<i>Recipient Name:</i> Johns Hopkins Bloomberg Center for Public Health <i>Grant / Contract Description:</i> RSV prevention clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Novavax	Grant / Contract	Other - Institution
<i>Recipient Name:</i> Johns Hopkins Bloomberg Center for Public Health <i>Grant / Contract Description:</i> RSV vaccine clinical trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Pfizer	Grant / Contract	Other - Institution
<i>Recipient Name:</i> Johns Hopkins Bloomberg Center for Public Health <i>Grant / Contract Description:</i> COVID-19 vaccine trial <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> SVP and Head of vaccine R&D <i>Additional Information:</i>		<i>Position Description:</i> head of vaccine R&D
Pfizer	Stock	Self
<i>Additional Information:</i> as a Pfizer employee i hold PFE stock and stock options		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i> Full time employee		<i>Position Description:</i> Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Executive Director <i>Additional Information:</i>		<i>Position Description:</i> Head of Statistics and Modeling, Vaccine Clinical Research and Development
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i>		<i>Position Description:</i> Vaccine Research and Development

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President <i>Additional Information:</i>		<i>Position Description:</i> Clinical Research Head Vaccines Europe and Asia Pacific
Pfizer	Stock	Self
<i>Additional Information:</i>		
Pfizer	Stock Option	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i>		<i>Position Description:</i> Safety physician
Pfizer	Stock	Self
<i>Additional Information:</i> Stock and stock options based on employment policies		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Vice President Vaccine Clinical Research & Development		<i>Position Description:</i>
<i>Additional Information:</i>		

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Meningococcal Pentavalent vaccine	No	Self
<i>Description:</i> Meningococcal Pentavalent vaccine	<i>Patent Number:</i> 10,813,989 B2	
<i>Patent Status:</i> Issued	<i>Patent Holder:</i> Current Institution	
<i>Filing Jurisdiction:</i> USA		
<i>Licensees:</i>	<i>Additional Information:</i>	

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization	Type	Interest Held By
iTrials SA <i>Additional Information:</i> scientific site management organization	Stock	Self
Janssen Biotech <i>Category:</i> Consultant <i>Additional Information:</i>	Consultant	Self <i>Description:</i> consultation on RSV
Merck <i>Category:</i> Consultant <i>Additional Information:</i>	Consultant	Self <i>Description:</i> consultation on RSV
Novavax, INC <i>Category:</i> Consultant <i>Additional Information:</i>	Consultant	Self <i>Description:</i> consultation on RSV

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Boehringer Ingelheim	Other	Self
Category: Other Additional Information: Phase III. Pulmonary Fibrosis treatment in adolescents. As Principal Investigator. I have signed an FDA FORM 1572 and received funds.		Description: Clinical Trial
Janssen Biotech	Other	Self
Category: Other Additional Information: Pediatric RSV antiviral treatment. Principal Investigator. - I have signed a FDA Form 1572 or an Investigator Agreement. - I have received funds and compensation to attend to an investigator meeting.		Description: Clinical Trial
Medicago	Other	Self
Category: Other Additional Information: SARS COV-2 vaccine against COVID-19. Principal Investigator. I have signed a FDA Form 1572 or an Investigator Agreement. I receive funds.		Description: Clinical Trial
Merck	Other	Self
Category: Other Additional Information: Anti-RSV Antibody in Newborns. Sub-Investigator. I have signed a FDA Form 1572 or an Investigator Agreement. I have received funds.		Description: Clinical Trial
Pfizer	Other	Self
Category: Other Additional Information: 1. Anti-RSV vaccine in pregnant women. Principal Investigator (2021-?) 2. Pediatric Antireflux treatment. Principal Investigator. (2019-?) 3. SARS COV-2 RNA vaccine against COVID19. Sub-Investigator. (2021-?) - In every study I have signed a FDA Form 1572 or an Investigator Agreement. - In every study I have received funds and compensation to attend to an investigator meeting.		Description: Clinical Trials

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Novartis Pharma	Stock	Self
<i>Additional Information:</i>		
Pfizer Inc.	Employment	Self
<i>Title:</i> Senior Director		<i>Position Description:</i> Biostatistician
<i>Additional Information:</i>		
Pfizer Inc.	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Executive Officer, Co-Founder		<i>Position Description:</i> Member of the Board
<i>Additional Information:</i>		
biontech	Stock	Self
<i>Additional Information:</i>		
biontech	Stock Option	Self
<i>Additional Information:</i>		

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - 3 UTR Sequences for stabilisation of mRNA	Yes	Self
<i>Description:</i> 3 UTR Sequences for stabilisation of mRNA		<i>Patent Number:</i> EPPCT/EP2015/073180, US 20190071682
<i>Patent Status:</i> Pending		<i>Patent Holder:</i> Previous Institution
<i>Filing Jurisdiction:</i> USA		<i>Additional Information:</i> I am co-inventors on various patents on RNA Technologies, both pending and granted, which have been filed over a period of 10+ years, some of which are licensed to third parties.
<i>Licensees:</i>		Jurisdictions are Broad including US, EU, Asia.
Licensee	Title	Date
biontech		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine,
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Director, Viral Vaccines <i>Additional Information:</i>		<i>Position Description:</i> vaccine research and development
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Clover Biopharmaceuticals	End Point Review Committee	Self
<i>Category:</i> End Point Review Committee <i>Additional Information:</i> adjudicate covid cases reported during conduct of covid vaccine trial		<i>Description:</i> case adjudication committee
Icosavax	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i> on the DSMB for covid vaccine trial, no meetings yet		<i>Description:</i> covid vaccine DSMB
Pfizer	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> 350/hr, one time consultation, contract expired 31 MAR 2021, no funds received to date		<i>Description:</i> one time consultation for DEC 2020 VRBPAC preparation and attendance

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

Yes.

 - Please describe those relationships.**

for transparency, I am an investigator on the Pfizer phase 1,2,3 covid vaccine trial, the relationship is between Pfizer and my University
- What is the manuscript title?**

Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**

No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Senior Director <i>Additional Information:</i>		<i>Position Description:</i>
Pfizer	Stock	Self
<i>Additional Information:</i>		

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Safety, Immunogenicity, and Efficacy of the BNT162b2 COVID-19 Vaccine in Adolescents
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
biontech	Employment	Self
<i>Title:</i> Chief Medical Officer <i>Additional Information:</i>		<i>Position Description:</i> Board member, CO-founder
biontech	Fiduciary Officer	Self
<i>Official Title:</i> Chief Medical Officer <i>Additional Information:</i> also spouse is co-founder and board member (Chief Executive Officer) of Biontech		<i>Position Description:</i> board member, co-founder
biontech	Fiduciary Officer	Spouse/Partner
<i>Official Title:</i> CEO <i>Additional Information:</i>		<i>Position Description:</i>
biontech	Stock	Spouse/Partner
<i>Additional Information:</i> founder, shareholder		
biontech	Stock Option	Self
<i>Additional Information:</i> self and spouse have stock Options. spouse has stock		

Intellectual Property

Type	Is Licensed	Interest Held By						
Patent - Modifications of RNA leading to increased transc ...	Yes	Self						
<i>Description:</i> Modifications of RNA leading to increased transcript stability and translational efficiency <i>Patent Status:</i> Pending <i>Filing Jurisdiction:</i> USA <i>Licensees:</i>		<i>Patent Number:</i> EP1934345B9, DE102005046490.4 <i>Patent Holder:</i> Current Institution <i>Additional Information:</i> self and spouse are co-inventors on patents on RNA Tech						
<table border="1"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>biontech</td> <td></td> <td></td> </tr> </tbody> </table>	Licensee	Title	Date	biontech				
Licensee	Title	Date						
biontech								

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
- What is the manuscript title?
Six month safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
- Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
Pfizer Turkey	Grant / Contract	Self
<i>Recipient Name:</i> Serhat Unal <i>Grant / Contract Description:</i> Hacettepe University <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-10345

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Pfizer	Employment	Self
<i>Title:</i> Sr. Director, Vaccine Statistics <i>Additional Information:</i>		<i>Position Description:</i> Design, conduct, and analysis of vaccine clinical trials

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-10345

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-10345

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

